메뉴 건너뛰기




Volumn , Issue , 2010, Pages 315-343

Inhibition of Druga-Metabolizing Enzymes in the Gastrointestinal Tract and Its Influence on the Drug-Drug Interaction Prediction

Author keywords

Drug metabolizing enzyme inhibition; Intestinal inhibition in prediction strategy; Metabolic enzymes and transporters in human small intestine

Indexed keywords


EID: 84884461682     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470538951.ch9     Document Type: Chapter
Times cited : (1)

References (157)
  • 1
    • 40549102421 scopus 로고    scopus 로고
    • Assessment of the absorption, metabolism and absolute bioavailability of maraviroc in healthy male subjects
    • Abel S, Russell D, Whitlock LA, Ridgway CE, Nedderman AN, Walker DK. Assessment of the absorption, metabolism and absolute bioavailability of maraviroc in healthy male subjects. Br J Clin Pharmacol 2008; 65 ( Suppl 1 ): 60-67.
    • (2008) Br J Clin Pharmacol , vol.65 , Issue.SUPPL..1 , pp. 60-67
    • Abel, S.1    Russell, D.2    Whitlock, L.A.3    Ridgway, C.E.4    Nedderman, A.N.5    Walker, D.K.6
  • 2
    • 0035478779 scopus 로고    scopus 로고
    • Predicting the impact of physiological and biochemical processes on oral drug bioavailability
    • Agoram B, Woltosz WS, Bolger MB. Predicting the impact of physiological and biochemical processes on oral drug bioavailability. Adv Drug Deliv Rev 2001; 50 ( Suppl 1 ): S41-S67.
    • (2001) Adv Drug Deliv Rev , vol.50 , Issue.SUPPL..1
    • Agoram, B.1    Woltosz, W.S.2    Bolger, M.B.3
  • 4
    • 0026099498 scopus 로고
    • Interaction of citrus juices with felodipine and nifedipine
    • Bailey DG, Spence JD, Munoz C, Arnold JM. Interaction of citrus juices with felodipine and nifedipine. Lancet 1991; 337: 268-269.
    • (1991) Lancet , vol.337 , pp. 268-269
    • Bailey, D.G.1    Spence, J.D.2    Munoz, C.3    Arnold, J.M.4
  • 7
    • 2442719906 scopus 로고    scopus 로고
    • Unmasking the dynamic interplay between efflux transporters and metabolic enzymes
    • Benet LZ, Cummins CL, Wu CY. Unmasking the dynamic interplay between efflux transporters and metabolic enzymes. Int J Pharm 2004; 277: 3-9.
    • (2004) Int J Pharm , vol.277 , pp. 3-9
    • Benet, L.Z.1    Cummins, C.L.2    Wu, C.Y.3
  • 13
    • 27444445468 scopus 로고    scopus 로고
    • Prediction of in vivo drug-drug interactions from in vitro data: impact of incorporating parallel pathways of drug elimination and inhibitor absorption rate constant
    • Brown HS, Ito K, Galetin A, Houston JB. Prediction of in vivo drug-drug interactions from in vitro data: impact of incorporating parallel pathways of drug elimination and inhibitor absorption rate constant. Br J Clin Pharmacol 2005; 60: 508-518.
    • (2005) Br J Clin Pharmacol , vol.60 , pp. 508-518
    • Brown, H.S.1    Ito, K.2    Galetin, A.3    Houston, J.B.4
  • 14
    • 33748946044 scopus 로고    scopus 로고
    • Prediction of in vivo drug-drug interactions from in vitro data: factors affecting prototypic drug-drug interactions involving CYP2C9, CYP2D6 and CYP3A4
    • Brown HS, Galetin A, Hallifax D, Houston JB. Prediction of in vivo drug-drug interactions from in vitro data: factors affecting prototypic drug-drug interactions involving CYP2C9, CYP2D6 and CYP3A4. Clin Pharmacokinet 2006; 45: 1035-1050.
    • (2006) Clin Pharmacokinet , vol.45 , pp. 1035-1050
    • Brown, H.S.1    Galetin, A.2    Hallifax, D.3    Houston, J.B.4
  • 16
    • 0035192078 scopus 로고    scopus 로고
    • Hepatic and intestinal cytochrome P450 3A activity in cirrhosis: effects of transjugular intrahepatic portosystemic shunts
    • Chalasani N, Gorski JC, Patel NH, Hall SD, Galinsky RE. Hepatic and intestinal cytochrome P450 3A activity in cirrhosis: effects of transjugular intrahepatic portosystemic shunts. Hepatology 2001; 34: 1103-1108.
    • (2001) Hepatology , vol.34 , pp. 1103-1108
    • Chalasani, N.1    Gorski, J.C.2    Patel, N.H.3    Hall, S.D.4    Galinsky, R.E.5
  • 19
    • 0032772669 scopus 로고    scopus 로고
    • Effect of fluvoxamine on the pharmacokinetics of quinidine
    • Damkier P, Hansen LL, Brosen K. Effect of fluvoxamine on the pharmacokinetics of quinidine. Eur J Clin Pharmacol 1999; 55: 451-456.
    • (1999) Eur J Clin Pharmacol , vol.55 , pp. 451-456
    • Damkier, P.1    Hansen, L.L.2    Brosen, K.3
  • 20
    • 85047685271 scopus 로고    scopus 로고
    • Predictive models for oral drug absorption: from in silico methods to integrated dynamical models
    • Dokoumetzidis A, Kalantzi L, Fotaki N. Predictive models for oral drug absorption: from in silico methods to integrated dynamical models. Expert Opin Drug Metab Toxicol 2007; 3: 491-505.
    • (2007) Expert Opin Drug Metab Toxicol , vol.3 , pp. 491-505
    • Dokoumetzidis, A.1    Kalantzi, L.2    Fotaki, N.3
  • 21
    • 0242469224 scopus 로고    scopus 로고
    • The effects of fruit juices on drug disposition: a new model for drug interactions
    • Dresser GK, Bailey DG. The effects of fruit juices on drug disposition: a new model for drug interactions. Eur J Clin Invest 2003; 33 ( Suppl 2 ): 10-16.
    • (2003) Eur J Clin Invest , vol.33 , Issue.SUPPL.2 , pp. 10-16
    • Dresser, G.K.1    Bailey, D.G.2
  • 22
    • 0029055363 scopus 로고
    • Disposition of intravenous and oral cyclosporine after administration with grapefruit juice
    • Ducharme MP, Warbasse LH, Edwards DJ. Disposition of intravenous and oral cyclosporine after administration with grapefruit juice. Clin Pharmacol Ther 1995; 57: 485-491.
    • (1995) Clin Pharmacol Ther , vol.57 , pp. 485-491
    • Ducharme, M.P.1    Warbasse, L.H.2    Edwards, D.J.3
  • 24
    • 35648968125 scopus 로고    scopus 로고
    • Comparison of different approaches to predict metabolic drug-drug interactions
    • Einolf HJ. Comparison of different approaches to predict metabolic drug-drug interactions. Xenobiotica 2007; 37: 1257-1294.
    • (2007) Xenobiotica , vol.37 , pp. 1257-1294
    • Einolf, H.J.1
  • 26
    • 44349158401 scopus 로고    scopus 로고
    • Influence of fruit juices on drug disposition: discrepancies between in vitro and clinical studies
    • Farkas D, Greenblatt DJ. Influence of fruit juices on drug disposition: discrepancies between in vitro and clinical studies. Expert Opin Drug Metab Toxicol 2008; 4: 381-393.
    • (2008) Expert Opin Drug Metab Toxicol , vol.4 , pp. 381-393
    • Farkas, D.1    Greenblatt, D.J.2
  • 27
    • 33847113977 scopus 로고    scopus 로고
    • Pomegranate juice does not impair clearance of oral or intravenous midazolam, a probe for cytochrome P450-3A activity: comparison with grapefruit juice
    • Farkas D, Oleson LE, Zhao Y, Harmatz JS, Zinny MA, Court MH, Greenblatt DJ. Pomegranate juice does not impair clearance of oral or intravenous midazolam, a probe for cytochrome P450-3A activity: comparison with grapefruit juice. J Clin Pharmacol 2007; 47: 286-294.
    • (2007) J Clin Pharmacol , vol.47 , pp. 286-294
    • Farkas, D.1    Oleson, L.E.2    Zhao, Y.3    Harmatz, J.S.4    Zinny, M.A.5    Court, M.H.6    Greenblatt, D.J.7
  • 30
    • 0029786432 scopus 로고    scopus 로고
    • Differential induction of prehepatic and hepatic metabolism of verapamil by rifampin
    • Fromm MF, Busse D, Kroemer HK, Eichelbaum M. Differential induction of prehepatic and hepatic metabolism of verapamil by rifampin. Hepatology 1996; 24: 796-801.
    • (1996) Hepatology , vol.24 , pp. 796-801
    • Fromm, M.F.1    Busse, D.2    Kroemer, H.K.3    Eichelbaum, M.4
  • 32
    • 35348813095 scopus 로고    scopus 로고
    • Intestinal first-pass metabolism: bridging the gap between in vitro and in vivo
    • Galetin A. Intestinal first-pass metabolism: bridging the gap between in vitro and in vivo. Curr Drug Metab 2007; 8: 643-644.
    • (2007) Curr Drug Metab , vol.8 , pp. 643-644
    • Galetin, A.1
  • 33
    • 33747599176 scopus 로고    scopus 로고
    • Intestinal and hepatic metabolic activity of five cytochrome P450 enzymes: impact on prediction of first-pass metabolism
    • Galetin A, Houston JB. Intestinal and hepatic metabolic activity of five cytochrome P450 enzymes: impact on prediction of first-pass metabolism. J Pharmacol Exp Ther 2006; 318: 1220-1229.
    • (2006) J Pharmacol Exp Ther , vol.318 , pp. 1220-1229
    • Galetin, A.1    Houston, J.B.2
  • 34
    • 9444270510 scopus 로고    scopus 로고
    • Utility of recombinant enzyme kinetics in prediction of human clearance: impact of variability, CYP3A5, and CYP2C19 on CYP3A4 probe substrates
    • Galetin A, Brown C, Hallifax D, Ito K, Houston JB. Utility of recombinant enzyme kinetics in prediction of human clearance: impact of variability, CYP3A5, and CYP2C19 on CYP3A4 probe substrates. Drug Metab Dispos 2004; 32: 1411-1420.
    • (2004) Drug Metab Dispos , vol.32 , pp. 1411-1420
    • Galetin, A.1    Brown, C.2    Hallifax, D.3    Ito, K.4    Houston, J.B.5
  • 35
    • 29944446485 scopus 로고    scopus 로고
    • Prediction of time-dependent CYP3A4 drug-drug interactions: impact of enzyme degradation, parallel elimination pathways, and intestinal inhibition
    • Galetin A, Burt H, Gibbons L, Houston JB. Prediction of time-dependent CYP3A4 drug-drug interactions: impact of enzyme degradation, parallel elimination pathways, and intestinal inhibition. Drug Metab Dispos 2006; 34: 166-175.
    • (2006) Drug Metab Dispos , vol.34 , pp. 166-175
    • Galetin, A.1    Burt, H.2    Gibbons, L.3    Houston, J.B.4
  • 36
    • 23044500208 scopus 로고    scopus 로고
    • CYP3A4 substrate selection and substitution in the prediction of potential drug-drug interactions
    • Galetin A, Ito K, Hallifax D, Houston JB. CYP3A4 substrate selection and substitution in the prediction of potential drug-drug interactions. J Pharmacol Exp Ther 2005; 314: 180-190.
    • (2005) J Pharmacol Exp Ther , vol.314 , pp. 180-190
    • Galetin, A.1    Ito, K.2    Hallifax, D.3    Houston, J.B.4
  • 37
    • 35348880290 scopus 로고    scopus 로고
    • Maximal inhibition of intestinal first-pass metabolism as a pragmatic indicator of intestinal contribution to the drug-drug interactions for CYP3A4 cleared drugs
    • Galetin A, Hinton LK, Burt H, Obach RS, Houston JB. Maximal inhibition of intestinal first-pass metabolism as a pragmatic indicator of intestinal contribution to the drug-drug interactions for CYP3A4 cleared drugs. Curr Drug Metab 2007; 8: 685-693.
    • (2007) Curr Drug Metab , vol.8 , pp. 685-693
    • Galetin, A.1    Hinton, L.K.2    Burt, H.3    Obach, R.S.4    Houston, J.B.5
  • 38
    • 49649116162 scopus 로고    scopus 로고
    • Potential role of intestinal first-pass metabolism in the prediction of drug-drug interactions
    • Galetin A, Gertz M, Houston JB. Potential role of intestinal first-pass metabolism in the prediction of drug-drug interactions. Expert Opin Drug Metab Toxicol 2008; 4: 909-922.
    • (2008) Expert Opin Drug Metab Toxicol , vol.4 , pp. 909-922
    • Galetin, A.1    Gertz, M.2    Houston, J.B.3
  • 39
    • 58149347476 scopus 로고    scopus 로고
    • Grapefruit juice-drug interaction studies as a method to assess the extent of intestinal availability: utility and limitations
    • Gertz M, Davis JD, Harrison A, Houston JB, Galetin A. Grapefruit juice-drug interaction studies as a method to assess the extent of intestinal availability: utility and limitations. Curr Drug Metab 2008a; 9: 785-795.
    • (2008) Curr Drug Metab , vol.9 , pp. 785-795
    • Gertz, M.1    Davis, J.D.2    Harrison, A.3    Houston, J.B.4    Galetin, A.5
  • 40
    • 79951978003 scopus 로고    scopus 로고
    • Impact of permeability on in vitro predictions of intestinal availability in the QGut model
    • Gertz M, Fenner KS, Harrison A, Davis J, Houston JB, Galetin A. Impact of permeability on in vitro predictions of intestinal availability in the QGut model. Drug Metab Rev 2008b; 40 ( Suppl 1 ): 92.
    • (2008) Drug Metab Rev , vol.40 , Issue.SUPPL..1 , pp. 92
    • Gertz, M.1    Fenner, K.S.2    Harrison, A.3    Davis, J.4    Houston, J.B.5    Galetin, A.6
  • 41
    • 0032956839 scopus 로고    scopus 로고
    • Inhibition of cytochrome P-450 3A (CYP3A) in human intestinal and liver microsomes: comparison of Ki values and impact of CYP3A5 expression
    • Gibbs MA, Thummel KE, Shen DD, Kunze KL. Inhibition of cytochrome P-450 3A (CYP3A) in human intestinal and liver microsomes: comparison of Ki values and impact of CYP3A5 expression. Drug Metab Dispos 1999; 27: 180-187.
    • (1999) Drug Metab Dispos , vol.27 , pp. 180-187
    • Gibbs, M.A.1    Thummel, K.E.2    Shen, D.D.3    Kunze, K.L.4
  • 48
    • 0024566284 scopus 로고
    • Cyclosporin-erythromycin interaction in renal transplant patients
    • Gupta SK, Bakran A, Johnson RW, Rowland M. Cyclosporin-erythromycin interaction in renal transplant patients. Br J Clin Pharmacol 1989; 27: 475-481.
    • (1989) Br J Clin Pharmacol , vol.27 , pp. 475-481
    • Gupta, S.K.1    Bakran, A.2    Johnson, R.W.3    Rowland, M.4
  • 50
    • 0026457407 scopus 로고
    • Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction
    • Hebert MF, Roberts JP, Prueksaritanont T, Benet LZ. Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction. Clin Pharmacol Ther 1992; 52: 453-457.
    • (1992) Clin Pharmacol Ther , vol.52 , pp. 453-457
    • Hebert, M.F.1    Roberts, J.P.2    Prueksaritanont, T.3    Benet, L.Z.4
  • 51
    • 42049097101 scopus 로고    scopus 로고
    • Multiple inhibition mechanisms and prediction of drug-drug interactions: status of metabolism and transporter models as exemplified by gemfibrozil-drug interactions
    • Hinton LK, Galetin A, Houston JB. Multiple inhibition mechanisms and prediction of drug-drug interactions: status of metabolism and transporter models as exemplified by gemfibrozil-drug interactions. Pharm Res 2008; 25: 1063-1074.
    • (2008) Pharm Res , vol.25 , pp. 1063-1074
    • Hinton, L.K.1    Galetin, A.2    Houston, J.B.3
  • 53
    • 24344439264 scopus 로고    scopus 로고
    • Transporters and drug therapy: implications for drug disposition and disease
    • Ho RH, Kim RB. Transporters and drug therapy: implications for drug disposition and disease. Clin Pharmacol Ther 2005; 78: 260-277.
    • (2005) Clin Pharmacol Ther , vol.78 , pp. 260-277
    • Ho, R.H.1    Kim, R.B.2
  • 56
    • 0346992330 scopus 로고    scopus 로고
    • Progress towards prediction of human pharmacokinetic parameters from in vitro technologies
    • Houston JB, Galetin A. Progress towards prediction of human pharmacokinetic parameters from in vitro technologies. Drug Metab Rev 2003; 35: 393-415.
    • (2003) Drug Metab Rev , vol.35 , pp. 393-415
    • Houston, J.B.1    Galetin, A.2
  • 57
    • 10044251943 scopus 로고    scopus 로고
    • Modelling atypical CYP3A4 kinetics: principles and pragmatism
    • Houston JB, Galetin A. Modelling atypical CYP3A4 kinetics: principles and pragmatism. Arch Biochem Biophys 2005; 433: 351-360.
    • (2005) Arch Biochem Biophys , vol.433 , pp. 351-360
    • Houston, J.B.1    Galetin, A.2
  • 58
    • 60749133620 scopus 로고    scopus 로고
    • Methods for predicting in vivo pharmacokinetics using data from in vitro assays
    • Houston JB, Galetin A. Methods for predicting in vivo pharmacokinetics using data from in vitro assays. Curr Drug Metab 2008; 9: 940-951.
    • (2008) Curr Drug Metab , vol.9 , pp. 940-951
    • Houston, J.B.1    Galetin, A.2
  • 59
    • 33846577441 scopus 로고    scopus 로고
    • Drug interaction studies: study design, data analysis, and implications for dosing and labeling
    • Huang SM, Temple R, Throckmorton DC, Lesko LJ. Drug interaction studies: study design, data analysis, and implications for dosing and labeling. Clin Pharmacol Ther 2007; 81: 298-304.
    • (2007) Clin Pharmacol Ther , vol.81 , pp. 298-304
    • Huang, S.M.1    Temple, R.2    Throckmorton, D.C.3    Lesko, L.J.4
  • 64
    • 0033007704 scopus 로고    scopus 로고
    • Effects of intestinal CYP3A4 and P-glycoprotein on oral drug absorption-theoretical approach
    • Ito K, Kusuhara H, Sugiyama Y. Effects of intestinal CYP3A4 and P-glycoprotein on oral drug absorption-theoretical approach. Pharmaceutical Research 1999; 16: 225-231.
    • (1999) Pharmaceutical Research , vol.16 , pp. 225-231
    • Ito, K.1    Kusuhara, H.2    Sugiyama, Y.3
  • 65
    • 1942455361 scopus 로고    scopus 로고
    • Database analyses for the prediction of in vivo drug-drug interactions from in vitro data
    • Ito K, Brown HS, Houston JB. Database analyses for the prediction of in vivo drug-drug interactions from in vitro data. Br J Clin Pharmacol 2004; 57: 473-486.
    • (2004) Br J Clin Pharmacol , vol.57 , pp. 473-486
    • Ito, K.1    Brown, H.S.2    Houston, J.B.3
  • 66
    • 18844369894 scopus 로고    scopus 로고
    • Impact of parallel pathways of drug elimination and multiple cytochrome P450 involvement on drug-drug interactions: CYP2D6 paradigm
    • Ito K, Hallifax D, Obach RS, Houston JB. Impact of parallel pathways of drug elimination and multiple cytochrome P450 involvement on drug-drug interactions: CYP2D6 paradigm. Drug Metab Dispos 2005; 33: 837-844.
    • (2005) Drug Metab Dispos , vol.33 , pp. 837-844
    • Ito, K.1    Hallifax, D.2    Obach, R.S.3    Houston, J.B.4
  • 67
    • 0033994866 scopus 로고    scopus 로고
    • Quantitative prediction of in vivo drug-drug interactions from in vitro data based on physiological pharmacokinetics: use of maximum unbound concentration of inhibitor at the inlet to the liver
    • Kanamitsu S, Ito K, Sugiyama Y. Quantitative prediction of in vivo drug-drug interactions from in vitro data based on physiological pharmacokinetics: use of maximum unbound concentration of inhibitor at the inlet to the liver. Pharm Res 2000; 17: 336-343.
    • (2000) Pharm Res , vol.17 , pp. 336-343
    • Kanamitsu, S.1    Ito, K.2    Sugiyama, Y.3
  • 69
    • 4544253622 scopus 로고    scopus 로고
    • Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone
    • Kharasch ED, Hoffer C, Whittington D, Sheffels P. Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone. Clin Pharmacol Ther 2004a; 76: 250-269.
    • (2004) Clin Pharmacol Ther , vol.76 , pp. 250-269
    • Kharasch, E.D.1    Hoffer, C.2    Whittington, D.3    Sheffels, P.4
  • 70
    • 7944237810 scopus 로고    scopus 로고
    • Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary meiosis
    • Kharasch ED, Walker A, Hoffer C, Sheffels P. Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary meiosis. Clin Pharmacol Ther 2004b; 76: 452-466.
    • (2004) Clin Pharmacol Ther , vol.76 , pp. 452-466
    • Kharasch, E.D.1    Walker, A.2    Hoffer, C.3    Sheffels, P.4
  • 72
    • 34247184192 scopus 로고    scopus 로고
    • Grapefruit juice, a glass full of drug interactions?
    • Kirby BJ, Unadkat JD. Grapefruit juice, a glass full of drug interactions? Clin Pharmacol Ther 2007; 81: 631-633.
    • (2007) Clin Pharmacol Ther , vol.81 , pp. 631-633
    • Kirby, B.J.1    Unadkat, J.D.2
  • 73
    • 9444267085 scopus 로고    scopus 로고
    • Functional interaction of intestinal CYP3A4 and P-glycoprotein
    • Kivisto KT, Niemi M, Fromm MF. Functional interaction of intestinal CYP3A4 and P-glycoprotein. Fundam Clin Pharmacol 2004; 18: 621-626.
    • (2004) Fundam Clin Pharmacol , vol.18 , pp. 621-626
    • Kivisto, K.T.1    Niemi, M.2    Fromm, M.F.3
  • 75
    • 45349101688 scopus 로고    scopus 로고
    • Species differences in in vitro and in vivo small intestinal metabolism of CYP3A substrates
    • Komura H, Iwaki M. Species differences in in vitro and in vivo small intestinal metabolism of CYP3A substrates. J Pharm Sci 2007.
    • (2007) J Pharm Sci
    • Komura, H.1    Iwaki, M.2
  • 76
    • 0031784578 scopus 로고    scopus 로고
    • Effect of grapefruit juice on the pharmacokinetics of microemulsion cyclosporine and its metabolite in healthy volunteers: does the formulation difference matter?
    • Ku YM, Min DI, Flanigan M. Effect of grapefruit juice on the pharmacokinetics of microemulsion cyclosporine and its metabolite in healthy volunteers: does the formulation difference matter? J Clin Pharmacol 1998; 38: 959-965.
    • (1998) J Clin Pharmacol , vol.38 , pp. 959-965
    • Ku, Y.M.1    Min, D.I.2    Flanigan, M.3
  • 81
    • 33846571368 scopus 로고    scopus 로고
    • Effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers
    • Lau YY, Huang Y, Frassetto L, Benet LZ. effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers. Clin Pharmacol Ther 2007; 81: 194-204.
    • (2007) Clin Pharmacol Ther , vol.81 , pp. 194-204
    • Lau, Y.Y.1    Huang, Y.2    Frassetto, L.3    Benet, L.Z.4
  • 82
    • 0036908935 scopus 로고    scopus 로고
    • Application of semisimultaneous midazolam administration for hepatic and intestinal cytochrome P450 3A phenotyping
    • Lee JI, Chaves-Gnecco D, Amico JA, Kroboth PD, Wilson JW, Frye RF. Application of semisimultaneous midazolam administration for hepatic and intestinal cytochrome P450 3A phenotyping. Clin Pharmacol Ther 2002; 72: 718-728.
    • (2002) Clin Pharmacol Ther , vol.72 , pp. 718-728
    • Lee, J.I.1    Chaves-Gnecco, D.2    Amico, J.A.3    Kroboth, P.D.4    Wilson, J.W.5    Frye, R.F.6
  • 83
    • 0035126980 scopus 로고    scopus 로고
    • Effect of grapefruit juice on pharmacokinetics of microemulsion cyclosporine in African American subjects compared with Caucasian subjects: does ethnic difference matter?
    • Lee M, Min DI, Ku YM, Flanigan M. Effect of grapefruit juice on pharmacokinetics of microemulsion cyclosporine in African American subjects compared with Caucasian subjects: does ethnic difference matter? J Clin Pharmacol 2001; 41: 317-323.
    • (2001) J Clin Pharmacol , vol.41 , pp. 317-323
    • Lee, M.1    Min, D.I.2    Ku, Y.M.3    Flanigan, M.4
  • 84
    • 0242383181 scopus 로고    scopus 로고
    • Clinical pharmacokinetics of atorvastatin
    • Lennernas H. Clinical pharmacokinetics of atorvastatin. Clin Pharmacokinet 2003; 42: 1141-1160.
    • (2003) Clin Pharmacokinet , vol.42 , pp. 1141-1160
    • Lennernas, H.1
  • 85
    • 0037229942 scopus 로고    scopus 로고
    • Role of P-glycoprotein in pharmacokinetics: clinical implications
    • Lin JH, Yamazaki M. Role of P-glycoprotein in pharmacokinetics: clinical implications. Clin Pharmacokinet 2003; 42: 59-98.
    • (2003) Clin Pharmacokinet , vol.42 , pp. 59-98
    • Lin, J.H.1    Yamazaki, M.2
  • 86
    • 0030774776 scopus 로고    scopus 로고
    • In vivo assessment of intestinal drug metabolism
    • Lin JH, Chiba M, Baillie TA. In vivo assessment of intestinal drug metabolism. Drug Metab Dispos 1997; 25: 1107-1109.
    • (1997) Drug Metab Dispos , vol.25 , pp. 1107-1109
    • Lin, J.H.1    Chiba, M.2    Baillie, T.A.3
  • 87
    • 0033009998 scopus 로고    scopus 로고
    • Is the role of the small intestine in first-pass metabolism overemphasized?
    • Lin JH, Chiba M, Baillie TA. Is the role of the small intestine in first-pass metabolism overemphasized? Pharmacol Rev 1999; 51: 135-158.
    • (1999) Pharmacol Rev , vol.51 , pp. 135-158
    • Lin, J.H.1    Chiba, M.2    Baillie, T.A.3
  • 91
    • 0031001463 scopus 로고    scopus 로고
    • Effects of grapefruit juice ingestion-pharmacokinetics and haemodynamics of intravenously and orally administered felodipine in healthy men
    • Lundahl J, Regardh CG, Edgar B, Johnsson G. Effects of grapefruit juice ingestion-pharmacokinetics and haemodynamics of intravenously and orally administered felodipine in healthy men. Eur J Clin Pharmacol 1997; 52: 139-145.
    • (1997) Eur J Clin Pharmacol , vol.52 , pp. 139-145
    • Lundahl, J.1    Regardh, C.G.2    Edgar, B.3    Johnsson, G.4
  • 92
    • 0032815783 scopus 로고    scopus 로고
    • Comparison of CYP2D6 content and metoprolol oxidation between microsomes isolated from human livers and small intestines
    • Madani S, Paine MF, Lewis L, Thummel KE, Shen DD. Comparison of CYP2D6 content and metoprolol oxidation between microsomes isolated from human livers and small intestines. Pharm Res 1999; 16: 1199-1205.
    • (1999) Pharm Res , vol.16 , pp. 1199-1205
    • Madani, S.1    Paine, M.F.2    Lewis, L.3    Thummel, K.E.4    Shen, D.D.5
  • 93
    • 4744339424 scopus 로고    scopus 로고
    • In vivo comparisons of constitutive cytochrome P450 3A activity assessed by alprazolam, triazolam, and midazolam
    • Masica AL, Mayo G, Wilkinson GR. In vivo comparisons of constitutive cytochrome P450 3A activity assessed by alprazolam, triazolam, and midazolam. Clin Pharmacol Ther 2004; 76: 341-349.
    • (2004) Clin Pharmacol Ther , vol.76 , pp. 341-349
    • Masica, A.L.1    Mayo, G.2    Wilkinson, G.R.3
  • 94
    • 0036842039 scopus 로고    scopus 로고
    • Involvement of CYP2J2 on the intestinal first-pass metabolism of antihistamine drug, astemizole
    • Matsumoto S, Hirama T, Matsubara T, Nagata K, Yamazoe Y. Involvement of CYP2J2 on the intestinal first-pass metabolism of antihistamine drug, astemizole. Drug Metab Dispos 2002; 30: 1240-1245.
    • (2002) Drug Metab Dispos , vol.30 , pp. 1240-1245
    • Matsumoto, S.1    Hirama, T.2    Matsubara, T.3    Nagata, K.4    Yamazoe, Y.5
  • 95
    • 4644331461 scopus 로고    scopus 로고
    • Differences in the inhibition of cytochromes P450 3A4 and 3A5 by metabolite-inhibitor complex-forming drugs
    • McConn DJ, 2nd, Lin YS, Allen K, Kunze KL, Thummel KE. Differences in the inhibition of cytochromes P450 3A4 and 3A5 by metabolite-inhibitor complex-forming drugs. Drug Metab Dispos 2004; 32: 1083-1091.
    • (2004) Drug Metab Dispos , vol.32 , pp. 1083-1091
    • McConn II, D.J.1    Lin, Y.S.2    Allen, K.3    Kunze, K.L.4    Thummel, K.E.5
  • 96
    • 0142010611 scopus 로고    scopus 로고
    • P-glycoprotein increases from proximal to distal regions of human small intestine
    • Mouly S, Paine MF. P-glycoprotein increases from proximal to distal regions of human small intestine. Pharm Res 2003; 20: 1595-1599.
    • (2003) Pharm Res , vol.20 , pp. 1595-1599
    • Mouly, S.1    Paine, M.F.2
  • 97
    • 0036118848 scopus 로고    scopus 로고
    • Comparative human pharmacokinetics and metabolism of single-dose oral and intravenous sildenafil
    • Muirhead GJ, Rance DJ, Walker DK, Wastall P. Comparative human pharmacokinetics and metabolism of single-dose oral and intravenous sildenafil. Br J Clin Pharmacol 2002; 53 ( Suppl 1 ): 13S-20S.
    • (2002) Br J Clin Pharmacol , vol.53 , Issue.SUPPL.1
    • Muirhead, G.J.1    Rance, D.J.2    Walker, D.K.3    Wastall, P.4
  • 99
    • 0036121963 scopus 로고    scopus 로고
    • Pharmacokinetics of sildenafil after single oral doses in healthy male subjects: absolute bioavailability, food effects and dose proportionality
    • Nichols DJ, Muirhead GJ, Harness JA. Pharmacokinetics of sildenafil after single oral doses in healthy male subjects: absolute bioavailability, food effects and dose proportionality. Br J Clin Pharmacol 2002; 53 ( Suppl 1 ): 5S-12S.
    • (2002) Br J Clin Pharmacol , vol.53 , Issue.SUPPL.1
    • Nichols, D.J.1    Muirhead, G.J.2    Harness, J.A.3
  • 100
    • 34548103493 scopus 로고    scopus 로고
    • Role of OATP transporters in the disposition of drugs
    • Niemi M. Role of OATP transporters in the disposition of drugs. Pharmacogenomics 2007; 8: 787-802.
    • (2007) Pharmacogenomics , vol.8 , pp. 787-802
    • Niemi, M.1
  • 101
    • 0035118551 scopus 로고    scopus 로고
    • Metabolic characterization of the major human small intestinal cytochrome p450s
    • Obach RS, Zhang QY, Dunbar D, Kaminsky LS. Metabolic characterization of the major human small intestinal cytochrome p450s. Drug Metab Dispos 2001; 29: 347-352.
    • (2001) Drug Metab Dispos , vol.29 , pp. 347-352
    • Obach, R.S.1    Zhang, Q.Y.2    Dunbar, D.3    Kaminsky, L.S.4
  • 103
    • 33846449874 scopus 로고    scopus 로고
    • Mechanism-based inactivation of human cytochrome p450 enzymes and the prediction of drug-drug interactions
    • Obach RS, Walsky RL, Venkatakrishnan K. Mechanism-based inactivation of human cytochrome p450 enzymes and the prediction of drug-drug interactions. Drug Metab Dispos 2007; 35: 246-255.
    • (2007) Drug Metab Dispos , vol.35 , pp. 246-255
    • Obach, R.S.1    Walsky, R.L.2    Venkatakrishnan, K.3
  • 105
    • 0029664974 scopus 로고    scopus 로고
    • The effects of the systemic antimycotics, itraconazole and fluconazole, on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam
    • Olkkola KT, Ahonen J, Neuvonen PJ. The effects of the systemic antimycotics, itraconazole and fluconazole, on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. Anesth Analg 1996; 82: 511-516.
    • (1996) Anesth Analg , vol.82 , pp. 511-516
    • Olkkola, K.T.1    Ahonen, J.2    Neuvonen, P.J.3
  • 108
    • 0032963857 scopus 로고    scopus 로고
    • Cytochrome P-450 1A1 expression in human small bowel: interindividual variation and inhibition by ketoconazole
    • Paine MF, Schmiedlin-Ren P, Watkins PB. Cytochrome P-450 1A1 expression in human small bowel: interindividual variation and inhibition by ketoconazole. Drug Metab Dispos 1999; 27: 360-364.
    • (1999) Drug Metab Dispos , vol.27 , pp. 360-364
    • Paine, M.F.1    Schmiedlin-Ren, P.2    Watkins, P.B.3
  • 109
    • 14344258321 scopus 로고    scopus 로고
    • Two major grapefruit juice components differ in time to onset of intestinal CYP3A4 inhibition
    • Paine MF, Criss AB, Watkins PB. Two major grapefruit juice components differ in time to onset of intestinal CYP3A4 inhibition. J Pharmacol Exp Ther 2005; 312: 1151-1160.
    • (2005) J Pharmacol Exp Ther , vol.312 , pp. 1151-1160
    • Paine, M.F.1    Criss, A.B.2    Watkins, P.B.3
  • 112
    • 0032807936 scopus 로고    scopus 로고
    • Effect of saquinavir on the pharmacokinetics and pharmacodynamics of oral and intravenous midazolam
    • Palkama VJ, Ahonen J, Neuvonen PJ, Olkkola KT. Effect of saquinavir on the pharmacokinetics and pharmacodynamics of oral and intravenous midazolam. Clin Pharmacol Ther 1999; 66: 33-39.
    • (1999) Clin Pharmacol Ther , vol.66 , pp. 33-39
    • Palkama, V.J.1    Ahonen, J.2    Neuvonen, P.J.3    Olkkola, K.T.4
  • 113
    • 0345275778 scopus 로고    scopus 로고
    • Modeling of intestinal drug absorption: roles of transporters and metabolic enzymes (for the Gillette Review Series)
    • Pang KS. Modeling of intestinal drug absorption: roles of transporters and metabolic enzymes (for the Gillette Review Series). Drug Metab Dispos 2003; 31: 1507-1519.
    • (2003) Drug Metab Dispos , vol.31 , pp. 1507-1519
    • Pang, K.S.1
  • 114
    • 0042349753 scopus 로고    scopus 로고
    • Effects of grapefruit juice on intestinal P-glycoprotein: evaluation using digoxin in humans
    • Parker RB, Yates CR, Soberman JE, Laizure SC. Effects of grapefruit juice on intestinal P-glycoprotein: evaluation using digoxin in humans. Pharmacotherapy 2003; 23: 979-987.
    • (2003) Pharmacotherapy , vol.23 , pp. 979-987
    • Parker, R.B.1    Yates, C.R.2    Soberman, J.E.3    Laizure, S.C.4
  • 117
    • 34250329999 scopus 로고    scopus 로고
    • Intestinal UGTs as potential modifiers of pharmacokinetics and biological responses to drugs and xenobiotics
    • Ritter JK. Intestinal UGTs as potential modifiers of pharmacokinetics and biological responses to drugs and xenobiotics. Expert Opin Drug Metab Toxicol 2007; 3: 93-107.
    • (2007) Expert Opin Drug Metab Toxicol , vol.3 , pp. 93-107
    • Ritter, J.K.1
  • 118
    • 0036614033 scopus 로고    scopus 로고
    • The effects of portal shunts on intestinal cytochrome P450 3A activity
    • author reply
    • Rostami-Hodjegan A, Tucker GT. The effects of portal shunts on intestinal cytochrome P450 3A activity. Hepatology 35: 1549-1550; author reply 2002; 1550-1541.
    • (2002) Hepatology , vol.35
    • Rostami-Hodjegan, A.1    Tucker, G.T.2
  • 119
    • 13244287685 scopus 로고    scopus 로고
    • " In silico " simulations to assess the " in vivo " consequences of " in vitro " metabolic drug-drug interactions
    • Rostami-Hodjegan A, Tucker G. " In silico " simulations to assess the " in vivo " consequences of " in vitro " metabolic drug-drug interactions. Drug Discovery Today: Technologies 2004; 1: 441.
    • (2004) Drug Discovery Today: Technologies , vol.1 , pp. 441
    • Rostami-Hodjegan, A.1    Tucker, G.2
  • 120
    • 33947587274 scopus 로고    scopus 로고
    • Simulation and prediction of in vivo drug metabolism in human populations from in vitro data
    • Rostami-Hodjegan A, Tucker GT. Simulation and prediction of in vivo drug metabolism in human populations from in vitro data. Nat Rev Drug Discovery 2007; 6: 140.
    • (2007) Nat Rev Drug Discovery , vol.6 , pp. 140
    • Rostami-Hodjegan, A.1    Tucker, G.T.2
  • 122
    • 33645847236 scopus 로고    scopus 로고
    • Effect of voriconazole on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam
    • Saari TI, Laine K, Leino K, Valtonen M, Neuvonen PJ, Olkkola KT. Effect of voriconazole on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. Clin Pharmacol Ther 2006; 79: 362-370.
    • (2006) Clin Pharmacol Ther , vol.79 , pp. 362-370
    • Saari, T.I.1    Laine, K.2    Leino, K.3    Valtonen, M.4    Neuvonen, P.J.5    Olkkola, K.T.6
  • 123
    • 23644436684 scopus 로고    scopus 로고
    • Undesirable effects of citrus juice on the pharmacokinetics of drugs: focus on recent studies
    • Saito M, Hirata-Koizumi M, Matsumoto M, Urano T, Hasegawa R. Undesirable effects of citrus juice on the pharmacokinetics of drugs: focus on recent studies. Drug Saf 2005; 28: 677-694.
    • (2005) Drug Saf , vol.28 , pp. 677-694
    • Saito, M.1    Hirata-Koizumi, M.2    Matsumoto, M.3    Urano, T.4    Hasegawa, R.5
  • 125
    • 33644847684 scopus 로고    scopus 로고
    • Transporters as a determinant of drug clearance and tissue distribution
    • Shitara Y, Horie T, Sugiyama Y. Transporters as a determinant of drug clearance and tissue distribution. Eur J Pharm Sci 2006; 27: 425-446.
    • (2006) Eur J Pharm Sci , vol.27 , pp. 425-446
    • Shitara, Y.1    Horie, T.2    Sugiyama, Y.3
  • 126
    • 33748042671 scopus 로고    scopus 로고
    • Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions
    • Shitara Y, Sugiyama Y. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacol Ther 2006; 112: 71-105.
    • (2006) Pharmacol Ther , vol.112 , pp. 71-105
    • Shitara, Y.1    Sugiyama, Y.2
  • 127
  • 130
    • 0037378726 scopus 로고    scopus 로고
    • Segmental intestinal transporters and metabolic enzymes on intestinal drug absorption
    • Tam D, Tirona RG, Pang KS. Segmental intestinal transporters and metabolic enzymes on intestinal drug absorption. Drug Metab Dispos 2003; 31: 373-383.
    • (2003) Drug Metab Dispos , vol.31 , pp. 373-383
    • Tam, D.1    Tirona, R.G.2    Pang, K.S.3
  • 133
    • 21744436852 scopus 로고    scopus 로고
    • Cytochromes P450 and MDR1 mRNA expression along the human gastrointestinal tract
    • Thorn M, Finnstrom N, Lundgren S, Rane A, Loof L. Cytochromes P450 and MDR1 mRNA expression along the human gastrointestinal tract. Br J Clin Pharmacol 2005; 60: 54-60.
    • (2005) Br J Clin Pharmacol , vol.60 , pp. 54-60
    • Thorn, M.1    Finnstrom, N.2    Lundgren, S.3    Rane, A.4    Loof, L.5
  • 134
    • 36048955673 scopus 로고    scopus 로고
    • Gut instincts: CYP3A4 and intestinal drug metabolism
    • Thummel KE. Gut instincts: CYP3A4 and intestinal drug metabolism. J Clin Invest 2007; 117: 3173-3176.
    • (2007) J Clin Invest , vol.117 , pp. 3173-3176
    • Thummel, K.E.1
  • 135
    • 0342437515 scopus 로고    scopus 로고
    • Enzyme-catalyzed processes of first-pass hepatic and intestinal drug extraction
    • Thummel KE, Kunze KL, Shen DD. Enzyme-catalyzed processes of first-pass hepatic and intestinal drug extraction. Adv Drug Delivery Rev 1997; 27: 99-127.
    • (1997) Adv Drug Delivery Rev , vol.27 , pp. 99-127
    • Thummel, K.E.1    Kunze, K.L.2    Shen, D.D.3
  • 137
    • 0032700543 scopus 로고    scopus 로고
    • Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole
    • Tsunoda SM, Velez RL, von Moltke LL, Greenblatt DJ. Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole. Clin Pharmacol Ther 1999; 66: 461-471.
    • (1999) Clin Pharmacol Ther , vol.66 , pp. 461-471
    • Tsunoda, S.M.1    Velez, R.L.2    von Moltke, L.L.3    Greenblatt, D.J.4
  • 138
    • 33746893861 scopus 로고    scopus 로고
    • In silico modeling of non-linear drug absorption for the P-gp substrate talinolol and of consequences for the resulting pharmacodynamic effect
    • Tubic M, Wagner D, Spahn-Langguth H, Bolger MB, Langguth P. In silico modeling of non-linear drug absorption for the P-gp substrate talinolol and of consequences for the resulting pharmacodynamic effect. Pharm Res 2006; 23: 1712-1720.
    • (2006) Pharm Res , vol.23 , pp. 1712-1720
    • Tubic, M.1    Wagner, D.2    Spahn-Langguth, H.3    Bolger, M.B.4    Langguth, P.5
  • 139
    • 0034883375 scopus 로고    scopus 로고
    • Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential-toward a consensus
    • Tucker GT, Houston JB, Huang SM. Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential-toward a consensus. Clin Pharmacol Ther 2001; 70: 103-114.
    • (2001) Clin Pharmacol Ther , vol.70 , pp. 103-114
    • Tucker, G.T.1    Houston, J.B.2    Huang, S.M.3
  • 140
    • 0035115599 scopus 로고    scopus 로고
    • Genetic multiplicity of the human UDP-glucuronosyltransferases and regulation in the gastrointestinal tract
    • Tukey RH, Strassburg CP. Genetic multiplicity of the human UDP-glucuronosyltransferases and regulation in the gastrointestinal tract. Mol Pharmacol 2001; 59: 405-414.
    • (2001) Mol Pharmacol , vol.59 , pp. 405-414
    • Tukey, R.H.1    Strassburg, C.P.2
  • 142
    • 18844426008 scopus 로고    scopus 로고
    • In vitro-in vivo extrapolation of CYP2D6 inactivation by paroxetine: prediction of nonstationary pharmacokinetics and drug interaction magnitude
    • Venkatakrishnan K, Obach RS. In vitro-in vivo extrapolation of CYP2D6 inactivation by paroxetine: prediction of nonstationary pharmacokinetics and drug interaction magnitude. Drug Metab Dispos 2005; 33: 845-852.
    • (2005) Drug Metab Dispos , vol.33 , pp. 845-852
    • Venkatakrishnan, K.1    Obach, R.S.2
  • 143
    • 1542376174 scopus 로고    scopus 로고
    • Cytochrome P450 3A4 and P-glycoprotein expression in human small intestinal enterocytes and hepatocytes: a comparative analysis in paired tissue specimens
    • von Richter O, Burk O, Fromm MF, Thon KP, Eichelbaum M, Kivisto KT. Cytochrome P450 3A4 and P-glycoprotein expression in human small intestinal enterocytes and hepatocytes: a comparative analysis in paired tissue specimens. Clin Pharmacol Ther 2004; 75: 172-183.
    • (2004) Clin Pharmacol Ther , vol.75 , pp. 172-183
    • von Richter, O.1    Burk, O.2    Fromm, M.F.3    Thon, K.P.4    Eichelbaum, M.5    Kivisto, K.T.6
  • 144
    • 0842282550 scopus 로고    scopus 로고
    • Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites
    • Wang YH, Jones DR, Hall SD. Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. Drug Metab Dispos 2004; 32: 259-266.
    • (2004) Drug Metab Dispos , vol.32 , pp. 259-266
    • Wang, Y.H.1    Jones, D.R.2    Hall, S.D.3
  • 146
    • 0342762062 scopus 로고    scopus 로고
    • The barrier function of CYP3A4 and P-glycoprotein in the small bowel
    • Watkins PB. The barrier function of CYP3A4 and P-glycoprotein in the small bowel. Adv Drug Delivery Rev 1997; 27: 161-170.
    • (1997) Adv Drug Delivery Rev , vol.27 , pp. 161-170
    • Watkins, P.B.1
  • 147
    • 0016566218 scopus 로고
    • Commentary: a physiological approach to hepatic drug clearance
    • Wilkinson GR, Shand DG. Commentary: a physiological approach to hepatic drug clearance. Clin Pharmacol Ther 1975; 18: 377-390.
    • (1975) Clin Pharmacol Ther , vol.18 , pp. 377-390
    • Wilkinson, G.R.1    Shand, D.G.2
  • 149
    • 17644380257 scopus 로고    scopus 로고
    • Predicting drug disposition via application of BCS: transport/ absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system
    • Wu CY, Benet LZ. Predicting drug disposition via application of BCS: transport/ absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm Res 2005; 22: 11-23.
    • (2005) Pharm Res , vol.22 , pp. 11-23
    • Wu, C.Y.1    Benet, L.Z.2
  • 151
    • 4744373595 scopus 로고    scopus 로고
    • Cytochrome P450 3A expression and activity in the human small intestine
    • Yang J, Tucker GT, Rostami-Hodjegan A. Cytochrome P450 3A expression and activity in the human small intestine. Clin Pharmacol Ther 2004; 76: 391.
    • (2004) Clin Pharmacol Ther , vol.76 , pp. 391
    • Yang, J.1    Tucker, G.T.2    Rostami-Hodjegan, A.3
  • 154
    • 47749122616 scopus 로고    scopus 로고
    • Cytochrome p450 turnover: regulation of synthesis and degradation, methods for determining rates, and implications for the prediction of drug interactions
    • Yang J, Liao M, Shou M, Jamei M, Yeo KR, Tucker GT, Rostami-Hodjegan A. Cytochrome p450 turnover: regulation of synthesis and degradation, methods for determining rates, and implications for the prediction of drug interactions. Curr Drug Metab 2008; 9: 384-394.
    • (2008) Curr Drug Metab , vol.9 , pp. 384-394
    • Yang, J.1    Liao, M.2    Shou, M.3    Jamei, M.4    Yeo, K.R.5    Tucker, G.T.6    Rostami-Hodjegan, A.7
  • 156
    • 0032888376 scopus 로고    scopus 로고
    • A compartmental absorption and transit model for estimating oral drug absorption
    • Yu LX, Amidon GL. A compartmental absorption and transit model for estimating oral drug absorption. Int J Pharm 1999; 186: 119-125.
    • (1999) Int J Pharm , vol.186 , pp. 119-125
    • Yu, L.X.1    Amidon, G.L.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.